MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS

摘要

The subject of the invention is a composition suitable for use as a medicinal product, comprising a mixture of active ingredients consisting of at least: a whey hydrolyzate with a molecular weight of between 200 and 5000 daltons, alpha lactalbumin, at least one activating pharmaceutical active principle of the AMPK, MAPK, PPAR α and γ and / or SIRT1 cycles, at least one nutritional regulator of the AMPK, MAPK, PPA R a and γ and / or SIRT1 cycles, of the milk calcium . It is particularly useful as a drug for the treatment and prevention of cardiometabolic risk, in particular for the prevention and treatment of cardiometabolic diseases, in particular cardiovascular diseases, fatty liver, hyperglycemia and insulin resistance, of the meadow. type II diabetes and type II diabetes.